You are here: Home Search
- Cost-effectiveness of zoledronic acid and strontium-89 as bone protecting treatments in addition to chemotherapy in patients with metastatic castrate-refractory prostate cancer: results from the TRAPEZE trial (ISRCTN 12808747).
- Survival Advantage with Total Intravenous Anesthesia in Cancer Surgery: Is This Confounded by Cancer Type and Stage?
- 6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial.
- Improving primary care identification of familial breast cancer risk using proactive invitation and decision support.